$BCTX
BriaCell Therapeutics Corp.

2023 Q4 Form 10-Q Financial Statement

#000149315223044892 Filed on December 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2022 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.646M $2.148M
YoY Change -23.38% 52.43%
% of Gross Profit
Research & Development $6.857M $3.255M
YoY Change 110.65% 271.75%
% of Gross Profit
Depreciation & Amortization $3.820K $3.818K
YoY Change 0.05% -0.05%
% of Gross Profit
Operating Expenses $8.503M $5.403M
YoY Change 57.37% 136.48%
Operating Profit -$8.503M -$5.403M
YoY Change 57.37% 136.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $14.46M $4.297M
YoY Change 236.59% -4124.17%
Pretax Income $5.959M -$1.107M
YoY Change -638.51% -53.63%
Income Tax
% Of Pretax Income
Net Earnings $6.002M -$1.107M
YoY Change -642.37% -53.63%
Net Earnings / Revenue
Basic Earnings Per Share $0.38 -$0.07
Diluted Earnings Per Share -$0.50 -$71.31K
COMMON SHARES
Basic Shares Outstanding 15.98M shares 15.52M shares
Diluted Shares Outstanding 16.67M shares 15.52M shares

Balance Sheet

Concept 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.65M $37.45M
YoY Change -63.56% -32.51%
Cash & Equivalents $13.65M $37.45M
Short-Term Investments
Other Short-Term Assets $4.741M $742.1K
YoY Change 538.81% 82.43%
Inventory
Prepaid Expenses $4.741M $742.1K
Receivables $21.41K $29.70K
Other Receivables $0.00 $0.00
Total Short-Term Assets $18.41M $38.22M
YoY Change -51.84% -31.64%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.00 $2.00
YoY Change 0.0%
Other Assets
YoY Change
Total Long-Term Assets $211.3K $226.5K
YoY Change -6.74% -6.32%
TOTAL ASSETS
Total Short-Term Assets $18.41M $38.22M
Total Long-Term Assets $211.3K $226.5K
Total Assets $18.62M $38.45M
YoY Change -51.58% -31.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.047M $791.8K
YoY Change 32.18% 229.83%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.047M $974.1K
YoY Change 7.44% 125.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $15.06M $27.14M
YoY Change -44.53% 8763.54%
Total Long-Term Liabilities $15.06M $27.14M
YoY Change -44.53% 8046.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.047M $974.1K
Total Long-Term Liabilities $15.06M $27.14M
Total Liabilities $16.10M $28.12M
YoY Change -42.73% 3577.46%
SHAREHOLDERS EQUITY
Retained Earnings -$74.65M -$61.46M
YoY Change 21.47%
Common Stock $69.59M $71.93M
YoY Change -3.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.721M $10.33M
YoY Change
Total Liabilities & Shareholders Equity $18.62M $38.45M
YoY Change -51.58% -31.53%

Cashflow Statement

Concept 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income $6.002M -$1.107M
YoY Change -642.37% -53.63%
Depreciation, Depletion And Amortization $3.820K $3.818K
YoY Change 0.05% -0.05%
Cash From Operating Activities -$7.605M -$3.542M
YoY Change 114.69% 99.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$47.29K
YoY Change
NET CHANGE
Cash From Operating Activities -$7.605M -$3.542M
Cash From Investing Activities
Cash From Financing Activities -$47.29K
Net Change In Cash -$7.605M -$3.590M
YoY Change 111.86% 101.83%
FREE CASH FLOW
Cash From Operating Activities -$7.605M -$3.542M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001610820
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2022Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
usd
CY2023Q4 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q4 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022Q4 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
CY2022Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2022Q4 BCTX Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
shares
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-10-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
001-40101
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
BRIACELL THERAPEUTICS CORP.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1099599
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
235 15th Street
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
West Vancouver
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V7T 2X1
CY2023Q4 dei City Area Code
CityAreaCode
604
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
921-1810
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
true
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15981726 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13645847 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21251092 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21410 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18873 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4740726 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5678542 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
18407983 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
26948507 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
2 usd
CY2023Q3 us-gaap Equity Method Investments
EquityMethodInvestments
2 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
211250 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
215068 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
211252 usd
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
215070 usd
CY2023Q4 us-gaap Assets
Assets
18619235 usd
CY2023Q3 us-gaap Assets
Assets
27163577 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
433915 usd
CY2023Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1123739 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
612590 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
677718 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1046505 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1801457 usd
CY2023Q4 BCTX Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
15056430 usd
CY2023Q3 BCTX Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
29139301 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
15056430 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
29139301 usd
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15981726 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15981726 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15981726 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15981726 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
69591784 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
69591784 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7918999 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7421950 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-205111 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74650688 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80652231 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2516300 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3777181 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18619235 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27163577 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6857257 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3255215 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1645771 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2147936 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
8503028 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
5403151 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8503028 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5403151 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14461900 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4296610 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
5958872 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-1106541 usd
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-42671 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
6001543 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1106541 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15518018 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16674891 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15518018 shares
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10328932 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1111941 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-1106541 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10334332 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3777181 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3777181 usd
CY2023Q4 BCTX Adjustments To Additional Paid In Capital Share Based Compensation Instruments Issued To Minority Shareholders At Arrangement Date
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationInstrumentsIssuedToMinorityShareholdersAtArrangementDate
-199207 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
533816 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
5958872 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2516300 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2516300 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
5958872 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-1106541 usd
CY2023Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3818 usd
CY2022Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3818 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
533816 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
1111941 usd
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14282078 usd
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4117790 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2537 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5595 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-937816 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-538822 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-689824 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
328468 usd
CY2023Q4 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-65128 usd
CY2022Q4 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-295505 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7605245 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3542382 usd
CY2022Q4 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
47294 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-47294 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7605245 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3589676 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21251092 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41041652 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13645847 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37451976 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74650688 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7605245 usd
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zspfHTaL61yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <span id="xdx_86A_z0MXSxeihXZk">Use of estimates</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13645847 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
21251092 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
15056430 usd
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
29139301 usd
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0 shares
CY2023Q4 us-gaap Share Price
SharePrice
4.25
CY2023Q3 us-gaap Share Price
SharePrice
6.69
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1693718 shares
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2131400 shares
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1693718 shares
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
533816 usd
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1111941 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
6001543 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1106541 usd
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15518018 shares
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6001543 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1106541 usd
CY2023Q4 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
-14282078 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8280535 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1106541 usd
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15981726 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15518018 shares
CY2023Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
211434 shares
CY2023Q4 BCTX Incremental Common Shares Attributable To Warrants
IncrementalCommonSharesAttributableToWarrants
481731 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16674891 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15518018 shares
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
190815 usd
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
188353 usd
CY2023Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14282078 usd
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4117790 usd
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10993 usd
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9533 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14461900 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4296610 usd

Files In Submission

Name View Source Status
0001493152-23-044892-index-headers.html Edgar Link pending
0001493152-23-044892-index.html Edgar Link pending
0001493152-23-044892.txt Edgar Link pending
0001493152-23-044892-xbrl.zip Edgar Link pending
bctx-20231031.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
bctx-20231031_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bctx-20231031_def.xml Edgar Link unprocessable
bctx-20231031_lab.xml Edgar Link unprocessable
bctx-20231031_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending